[go: up one dir, main page]

PE20010467A1 - 1,2,4,5-tetrahidro-benzo[d]azepin como antagonista del receptor metabotropico de glutamato - Google Patents

1,2,4,5-tetrahidro-benzo[d]azepin como antagonista del receptor metabotropico de glutamato

Info

Publication number
PE20010467A1
PE20010467A1 PE2000000768A PE0007682000A PE20010467A1 PE 20010467 A1 PE20010467 A1 PE 20010467A1 PE 2000000768 A PE2000000768 A PE 2000000768A PE 0007682000 A PE0007682000 A PE 0007682000A PE 20010467 A1 PE20010467 A1 PE 20010467A1
Authority
PE
Peru
Prior art keywords
alkyl
azepin
nitro
benzo
tetrahydro
Prior art date
Application number
PE2000000768A
Other languages
English (en)
Inventor
Alfred Binggeli
Hans-Peter Marki
Maurice Wilhelm
Geo Adam
Wolfgang Wostl
Vincent Mutel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20010467A1 publication Critical patent/PE20010467A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE 1,2,4,5-TETRAHIDROBENZO[d]AZEPIN DE FORMULA I, DONDE R1 ES H, ALQUILO, O, HALOGENO, OR, O-CICLOALQUILO C3-C6, -O(CHR)n-CICLOALQUILO C3-C6, ENTRE OTROS; n ES 1-6; R ES H, ALQUILO, ALQUENILO; R2 ES NITRO O CIANO; R3 ES H, ALQUILO, =O, =S, =SR, ENTRE OTROS; R4 ES H, ALQUILO, ALQUENILO, NITRO, OR, OCF3, OCF2-R, ENTRE OTROS; R5 Y R6 SON H, ALQUILO, ALCOXI, AMINO, NITRO, ENTRE OTROS; R7 Y R8 SON H, ALQUILO, ALCOXI, AMINO, NITRO, HALOGENO; R9 Y R10 SON H, ALQUILO; R11 Y R12 SON H, ALQUILO, OH, ALCOXI, ALCOXICARBONIL, ALCANOILOXI; R13 Y R14 SON H, TRITIO, ALQUILO; R14 Y R15 SON H, TRITIO, ALQUILO, OH, ALCOXI, ENTRE OTROS; X ES -N=, C=, ENTRE OTROS; Y ES -N=, NH, CH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 3-ETIL-2-METIL-5-NITRO-6-(1,2,4,5-TETRAHIDRO-BENZO[d]AZEPIN-3-IL)-3H-PIRIMIDIN-4-ONA, 2-AMINO-6-OXO-4-(1,2,4,5-TETRAHIDRO-BENZO[d]AZEPIN-3-IL)-1,6-DIHIDRO-PIRIMIDIN-5-CARBONITRILO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR METABOTROPICO DEL GLUTAMATO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE EPILEPSIA, DOLOR, PSICOSIS, ESQUIZOFRENIA, ALZHEIMER, DEFICIENCIAS DE MEMORIA, LESIONES OCULARES
PE2000000768A 1999-08-06 2000-08-02 1,2,4,5-tetrahidro-benzo[d]azepin como antagonista del receptor metabotropico de glutamato PE20010467A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99115557 1999-08-06

Publications (1)

Publication Number Publication Date
PE20010467A1 true PE20010467A1 (es) 2001-04-17

Family

ID=8238742

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000768A PE20010467A1 (es) 1999-08-06 2000-08-02 1,2,4,5-tetrahidro-benzo[d]azepin como antagonista del receptor metabotropico de glutamato

Country Status (27)

Country Link
US (1) US6218385B1 (es)
JP (1) JP3260350B2 (es)
KR (1) KR100390116B1 (es)
CN (1) CN1146455C (es)
AR (1) AR025035A1 (es)
AT (1) ATE254614T1 (es)
AU (1) AU774485B2 (es)
BR (1) BR0003375A (es)
CA (1) CA2314798A1 (es)
CO (1) CO5180625A1 (es)
DE (1) DE60006618T2 (es)
ES (1) ES2209728T3 (es)
HR (1) HRP20000520A2 (es)
HU (1) HUP0003112A3 (es)
ID (1) ID26743A (es)
IL (1) IL137688A0 (es)
MA (1) MA26748A1 (es)
NO (1) NO20003966L (es)
NZ (1) NZ506096A (es)
PE (1) PE20010467A1 (es)
PL (1) PL341890A1 (es)
RU (1) RU2240317C2 (es)
SG (1) SG93251A1 (es)
TR (1) TR200002298A3 (es)
UY (1) UY26276A1 (es)
YU (1) YU49700A (es)
ZA (1) ZA200003927B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1345609E (pt) * 2000-12-22 2005-08-31 Hoffmann La Roche Derivados de tetra-hidro-(benzo ou tieno)-azepina-pirazina como antagonistas de mglur 1
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
KR100765027B1 (ko) * 2002-12-20 2007-10-09 글락소 그룹 리미티드 신경 장애 치료용 벤즈아제핀 유도체
JP4782003B2 (ja) * 2003-06-17 2011-09-28 アリーナ ファーマシューティカルズ， インコーポレイテッド ５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体
EP2189448B1 (en) 2003-06-17 2014-01-29 Arena Pharmaceuticals, Inc. Processes for the Separation of 3-Benzazepine Racemates
US20080009478A1 (en) * 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
WO2005042490A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
SI1838677T1 (sl) 2004-12-21 2010-01-29 Arena Pharm Inc Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida
AU2005322183B2 (en) 2004-12-23 2012-03-29 Arena Pharmaceuticals, Inc. 5HT2C receptor modulator compositions and methods of use
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP5199997B2 (ja) * 2006-04-03 2013-05-15 アリーナ ファーマシューティカルズ， インコーポレイテッド ８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピンおよびこれに関連する中間体を調製するためのプロセス
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2610508T3 (es) 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
ES2522587T3 (es) * 2006-12-05 2014-11-17 Arena Pharmaceuticals, Inc. Procesos para preparar (R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzacepina e intermedios de la misma
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2288585A1 (en) 2008-03-04 2011-03-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102648170A (zh) 2009-06-18 2012-08-22 艾尼纳制药公司 制备5-ht2c受体激动剂的方法
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
CN103347523A (zh) 2010-09-01 2013-10-09 艾尼纳制药公司 向具有肾损伤的个体给药氯卡色林
EP2611782A1 (en) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
KR20130101524A (ko) 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
CN103189053A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 用于体重控制的5-ht2c激动剂的调节释放剂型
CA2886875A1 (en) 2012-10-09 2014-04-17 Arena Pharmaceuticals, Inc. Method of weight management

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206210A (en) * 1977-01-19 1980-06-03 Smithkline Corporation Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
WO1992007844A1 (en) * 1990-11-06 1992-05-14 Pfizer Inc. Quinazolines derivatives for enhancing antitumor activity
US5241065A (en) * 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors

Also Published As

Publication number Publication date
SG93251A1 (en) 2002-12-17
UY26276A1 (es) 2000-10-31
JP3260350B2 (ja) 2002-02-25
DE60006618T2 (de) 2004-09-23
ZA200003927B (en) 2001-02-06
ES2209728T3 (es) 2004-07-01
HUP0003112A3 (en) 2003-07-28
AU774485B2 (en) 2004-07-01
US6218385B1 (en) 2001-04-17
YU49700A (sh) 2003-04-30
TR200002298A2 (tr) 2001-03-21
IL137688A0 (en) 2001-10-31
BR0003375A (pt) 2001-03-13
TR200002298A3 (tr) 2001-03-21
KR20010082510A (ko) 2001-08-30
HUP0003112A2 (hu) 2002-11-28
HRP20000520A2 (en) 2001-06-30
CN1283623A (zh) 2001-02-14
ATE254614T1 (de) 2003-12-15
CO5180625A1 (es) 2002-07-30
PL341890A1 (en) 2001-02-12
KR100390116B1 (ko) 2003-07-04
RU2240317C2 (ru) 2004-11-20
HU0003112D0 (en) 2000-10-28
NO20003966L (no) 2001-02-07
ID26743A (id) 2001-02-08
DE60006618D1 (de) 2003-12-24
NZ506096A (en) 2002-08-28
JP2001089472A (ja) 2001-04-03
AR025035A1 (es) 2002-11-06
AU4897900A (en) 2001-02-08
CN1146455C (zh) 2004-04-21
CA2314798A1 (en) 2001-02-06
NO20003966D0 (no) 2000-08-04
MA26748A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
PE20010467A1 (es) 1,2,4,5-tetrahidro-benzo[d]azepin como antagonista del receptor metabotropico de glutamato
PE20010759A1 (es) Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico
PE20010681A1 (es) Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico
PE20021072A1 (es) DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2
RU98123001A (ru) Арилпиримидиновые производные
PE20060010A1 (es) 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20000170A1 (es) Derivados benzosulfonas
PE20011066A1 (es) PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
HUP0301671A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
PE58399A1 (es) Atropisomeros de 3-aril-4(3h)-quinazolinonas
CA2243234A1 (en) 5h-thiazolo[3,2-a]pyrimidine derivatives
PE20000422A1 (es) Compuestos de amidina
PE20010930A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
MY126586A (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
PE20011114A1 (es) Decahidro-isoquinolinas
PE18295A1 (es) Derivado de piperidina
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
IL123898A0 (en) Fused tropane derivatives their preparation and use
CY1105688T1 (el) Κυανοπυρρολες ως αγωνιστες υποδοχεων προγεστερονης
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
PE1998A1 (es) DERIVADOS DE BENZO [g] QUINOLINA
PE74899A1 (es) Derivados de ergolina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed